# PASW (Ping An Biomedical Co., Ltd.) - SEC EDGAR Financial Statements

> Ping An Biomedical Co., Ltd. reported ¥34.15M in revenue and a net loss of ¥12.83M for the fiscal year ended September 30, 2025 (down 61.0% year over year), with a 2.8% gross margin and a -43.1% operating margin.

- Canonical: https://convexityos.com/fundamentals/PASW
- Markdown: https://convexityos.com/fundamentals/PASW.md
- SEC CIK: 0001897532
- Reporting currency: CNY
- Latest filing period: September 30, 2025
- Last synced: Nov 21, 2026, 05:10 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001897532&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | ¥34.15M | -61.0% YoY |
| Operating Income | FY 2025 | -¥14.70M | -43.1% margin |
| Net Income | FY 2025 | -¥12.83M | -37.6% net margin |
| Diluted EPS | FY 2025 | -¥0.69 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2025 | ¥1.17M | Total debt: ¥10.47M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Revenue** | ¥34.15M | ¥87.62M | ¥82.56M |
| Cost of Revenue | ¥33.20M | ¥82.21M | ¥78.32M |
| **Gross Profit** | ¥950K | ¥5.42M | ¥4.24M |
| Selling, General & Admin | ¥6.31M | ¥5.30M | ¥3.60M |
| Total Operating Expenses | ¥15.65M | ¥5.42M | ¥3.63M |
| **Operating Income** | -¥14.70M | -¥2.0K | ¥612K |
| **EBITDA** | -¥14.70M | ¥8.2K | ¥645K |
| Interest Income | ¥326K | ¥2.0K | ¥156K |
| Interest Expense | ¥307K | ¥705K | ¥1.74M |
| Income Before Tax | -¥14.68M | -¥683K | ¥42K |
| Income Tax Expense | ¥1.86M | -¥601K | -¥1.04M |
| **Net Income** | -¥12.83M | -¥1.28M | -¥994K |
| Basic EPS | -¥0.69 | -¥0.07 | -¥0.06 |
| **Diluted EPS** | -¥0.69 | -¥0.07 | -¥0.06 |
| Basic Shares Outstanding | 18.5M | 18.0M | 18.0M |
| Diluted Shares Outstanding | 18.5M | 18.0M | 18.0M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | ¥1.17M | ¥131K |
| **Cash & Short-Term Investments** | ¥1.17M | ¥131K |
| Accounts Receivable, Net | ¥16.93M | ¥40.44M |
| Inventory | ¥442K | ¥127K |
| **Total Current Assets** | ¥63.70M | ¥53.31M |
| Property, Plant & Equipment, Net | -- | ¥5.6K |
| **Total Non-Current Assets** | ¥4.72M | ¥3.54M |
| **Total Assets** | ¥68.41M | ¥56.85M |
| Accounts Payable | ¥9.41M | ¥15.06M |
| Short-Term Debt | ¥10.00M | ¥10.00M |
| Deferred Revenue (Current) | ¥70K | ¥1.67M |
| **Total Current Liabilities** | ¥23.08M | ¥63.58M |
| **Total Non-Current Liabilities** | ¥96K | ¥461K |
| **Total Liabilities** | ¥23.17M | ¥64.04M |
| **Total Debt (incl. Leases)** | ¥10.47M | ¥10.81M |
| Common Stock | ¥8.4K | ¥7.3K |
| Retained Earnings | -¥21.05M | -¥8.22M |
| Accumulated Other Comp. Income | -¥1.61M | -¥657K |
| **Total Stockholders' Equity** | ¥45.24M | -¥7.19M |
| Total Equity | ¥45.24M | -¥7.19M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2025 | Sep 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | ¥1.17M | ¥131K |
| **Cash & Short-Term Investments** | ¥1.17M | ¥131K |
| Accounts Receivable, Net | ¥16.93M | ¥40.44M |
| Inventory | ¥442K | ¥127K |
| **Total Current Assets** | ¥63.70M | ¥53.31M |
| Property, Plant & Equipment, Net | -- | ¥5.6K |
| **Total Non-Current Assets** | ¥4.72M | ¥3.54M |
| **Total Assets** | ¥68.41M | ¥56.85M |
| Accounts Payable | ¥9.41M | ¥15.06M |
| Short-Term Debt | ¥10.00M | ¥10.00M |
| Deferred Revenue (Current) | ¥70K | ¥1.67M |
| **Total Current Liabilities** | ¥23.08M | ¥63.58M |
| **Total Non-Current Liabilities** | ¥96K | ¥461K |
| **Total Liabilities** | ¥23.17M | ¥64.04M |
| **Total Debt (incl. Leases)** | ¥10.47M | ¥10.81M |
| Common Stock | ¥8.4K | ¥7.3K |
| Retained Earnings | -¥21.05M | -¥8.22M |
| Accumulated Other Comp. Income | -¥1.61M | -¥657K |
| **Total Stockholders' Equity** | ¥45.24M | -¥7.19M |
| Total Equity | ¥45.24M | -¥7.19M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -¥12.83M | -¥1.28M | -¥994K |
| Depreciation & Amortization | ¥5.6K | ¥10K | ¥33K |
| Change in Receivables | ¥14.17M | ¥6.53M | ¥9.88M |
| Change in Inventory | -¥308K | ¥3.06M | ¥1.44M |
| Change in Payables | -¥5.64M | ¥5.78M | -¥8.76M |
| **Operating Cash Flow** | -¥6.43M | ¥14.63M | -¥6.08M |
| **Investing Cash Flow** | ¥0 | ¥15.00M | -¥3.37M |
| Dividends Paid | -- | -¥322K | -¥9.60M |
| **Financing Cash Flow** | ¥43.66M | -¥30.09M | ¥8.87M |
| **Net Change in Cash** | ¥37.23M | -¥459K | -¥576K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Gross Margin** | 2.8% | 6.2% | 5.1% |
| **Operating Margin** | -43.1% | 0.0% | 0.7% |
| **Net Profit Margin** | -37.6% | -1.5% | -1.2% |
| Return on Equity (ROE) | -28.4% | -- | -- |
| Return on Assets (ROA) | -18.8% | -2.3% | -- |
| Current Ratio | 2.76x | 0.84x | -- |
| Quick Ratio | 2.74x | 0.84x | -- |
| Debt to Equity | 0.23x | -- | -- |
| **Revenue Growth (YoY)** | -61.0% | +6.1% | -- |
| Gross Profit Growth (YoY) | -82.5% | +27.8% | -- |
| Operating Income Growth (YoY) | -- | -100.3% | -- |
| Operating Cash Flow Growth (YoY) | -143.9% | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
